Dernières nouvelles

Information non disponible

Bosch F, Cantin G, Cortelezzi A, Knauf W, Tiab M, Turgut M, Zaritskey A, Merot JL, Tausch E, Trunzer K, Robson S, Gresko E, Bottcher S, Foa R, Stilgenbauer S, Leblond V

Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study.

Article de revue

Leukemia, 34 (2), p. 441-450, 2020, ISSN: 0887-6924.

Résumé | Liens:

Lemieux J, Forget G, Brochu O, Provencher L, Cantin G, Desbiens C, Doyle C, Poirier B, Camden S, Durocher M

Evaluation of eligibility and recruitment in breast cancer clinical trials.

Article de revue

Breast, 23 (4), p. 385-92, 2014, ISSN: 0960-9776.

Résumé | Liens:

Poirier E, Desbiens C, Poirier B, Hogue JC, Lemieux J, Doyle C, Leblond AF, Cote I, Cantin G, Provencher L

Comparison of serious adverse events between the original and a generic docetaxel in breast cancer patients.

Article de revue

Ann Pharmacother, 48 (4), p. 447-55, 2014, ISSN: 1060-0280.

Résumé | Liens:

Stewart AK, Trudel S, Bahlis NJ, White D, Sabry W, Belch A, Reiman T, Roy J, Shustik C, Kovacs MJ, Rubinger M, Cantin G, Song K, Tompkins KA, Marcellus DC, Lacy MQ, Sussman J, Reece D, Brundage M, Harnett EL, Shepherd L, Chapman JA, Meyer RM

A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial.

Article de revue

Blood, 121 (9), p. 1517-23, 2013, ISSN: 0006-4971.

Résumé | Liens:

Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, Lopez-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N, MabThera International Trial (MInT) Group

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.

Article de revue

Lancet Oncol, 12 (11), p. 1013-22, 2011, ISSN: 1470-2045.

Résumé | Liens:

Sehn LH, MacDonald D, Rubin S, Cantin G, Rubinger M, Lemieux B, Basi S, Imrie K, Gascoyne RD, Sussman J, Chen BE, Djurfeldt M, Shepherd L, Couban S, Crump M

Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.

Article de revue

J Clin Oncol, 29 (25), p. 3396-401, 2011, ISSN: 0732-183X.

Résumé | Liens:

Signaler des ajouts ou des modifications